Внимание! Сравните стоимость вашего курса на выздоровление с рынком цен в Индии.
Изучите личный опыт форумчан, чтобы избежать «помощи» посредников.
(Для доступа к разделу требуется регистрация на форуме)
Модераторы: Nadine_Spb, Модераторы
![:]49](./images/smilies/49.gif "наше вам"){kind=small}
![:]38](./images/smilies/38.gif "всем привет!"){kind=small}
![:]80](./images/smilies/80.gif "M-m-m-m-m!"){kind=small}
Врачи, бывает, процент от лекарств получают - поэтому иногда загоняют на терапию без веских на то оснований. Если состояние печени более-менее - детей не стоит лечить (так как влияние терапии на растущий организм не изучено). До 18 не лечат пегами. IMHO, ребенка имеет смысл лечить, если у него сильный фиброз три или цирроз - что маловероятно в таком возрасте.Пенка писал(а):Официально да, в 18 лет пегами, но врач берется лечить в 16. Типа чем раньше, тем меньше побочек будет.
Возможно, фиброскан пока тестировался только на взрослых - т.е. вопрос в достоверности его показаний для детей.Пенка писал(а):Фиброскан отказали на основании, что его делают только с 18 лет!!! Интересно почему так?
![:]42](./images/smilies/42.gif "скалка"){kind=small}
![:]71](./images/smilies/71.gif "чужаяжена"){kind=small}
в общем, все как у взрослых. Сроки те же, побочки те же, дозы по весу рассчитывают... и эффективность, видимо, такая же...Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
marketwatch.com
KENILWORTH, N.J., Dec 12, 2008 /PRNewswire-FirstCall via COMTEX/ -- First and only approved peginterferon in combination with ribavirin for previously untreated children with chronic hepatitis C addresses unmet medical need
Schering-Plough Corporation (SGP:Schering-Plough Corporation) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) combination therapy for use in previously untreated patients 3 years of age and older with chronic hepatitis C. This represents the first and only approved peginterferon in combination with ribavirin for treating pediatric hepatitis C. It is estimated that approximately 130,000 children in the United States are infected with the hepatitis C virus (HCV). The most common mode of HCV infection for pediatric patients today is maternal-infant transmission.
The only previously approved therapy in the United States for treating pediatric hepatitis C is Schering-Plough's conventional interferon INTRON(R) A (Interferon alfa-2b, recombinant) in combination with REBETOL. REBETOL is available both as capsules and in an oral solution formulation specifically available for pediatric use.
"With the FDA approval of PEGINTRON combination therapy for this new indication, U.S. physicians now have access to the current standard of care for hepatitis C for use in treating their pediatric patients. Thankfully, the number of children with hepatitis C is small, although this chronic infection over time can lead to serious liver disease," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "This approval further underscores Schering-Plough's leadership and long-term commitment to developing new treatment options and innovative therapies to meet the needs of patients with hepatitis C."
The approval of PEGINTRON for the pediatric indication is based on the results of a clinical trial in 107 previously untreated patients 3 to 17 years of age with chronic hepatitis C and compensated liver disease. In the study, patients infected with HCV genotype 1 or 4 and those with HCV genotype 3 with HCV RNA greater than 600,000 IU/mL (high viral load [HVL]) were assigned 48 weeks of therapy, while those infected with HCV genotype 2 or 3 with HCV RNA less than 600,000 IU/mL (low viral load [LVL]) received 24 weeks of therapy. Of the patients with HCV genotype 1, 4 or 3 HVL who were assigned to 48 weeks of treatment, 55 percent achieved SVR. As with adult patients, SVR in pediatric patients with HCV genotype 2 or 3 LVL was much higher than in those with genotype 1; the SVR rate was 96 percent in children with HCV genotype 2 or 3 LVL.
In the pediatric population, the recommended dose of PEGINTRON, based on body surface area, is 60 mcg/m2/week subcutaneously in combination with 15 mg/kg/day of REBETOL, based on body weight, orally in two divided doses. The treatment duration for patients with HCV genotype 1 is 48 weeks and for patients with HCV genotype 2 or 3 it is 24 weeks. Patients receiving PEGINTRON combination therapy (excluding those with HCV genotype 2 or 3) should be discontinued from therapy at week 12 if their HCV RNA dropped less than 2 log10 compared to pretreatment or at 24 weeks if they have detectable HCV RNA at treatment week 24.
During the course of therapy lasting up to 48 weeks in patients 3 to 17 years of age, weight loss and growth inhibition were common. Some children who experienced growth inhibition during therapy still had inhibited growth velocity 6 months following the end of treatment. Most common adverse reactions (more than 25 percent) observed in these studies were pyrexia, headache, neutropenia, fatigue, anorexia, injection site erythema and vomiting. Three percent were treated for clinical hypothyroidism.
Dose modifications were required in 25 percent of patients, most commonly for anemia, neutropenia and weight loss. Therapy was discontinued prematurely in two percent of the patients.
SOURCE Schering-Plough Corporation
Арин, я с тобой полностью согласна, я говорила об этом Пенке, но я понимаю и ее - жить с мыслью, что у твоих деток какой-то вирусяга сидит невероятно сложно. время само все расставитАрин писал(а):Меня б коснулось -я б крепко подумала.
И подольше от переходного возраста потянула.
Все таки организм перестраивается- не шутки шути.
![:]21](./images/smilies/21.gif "Чмок!!"){kind=small}
![:]53](./images/smilies/53.gif "nozicka"){kind=small}
![:]12](./images/smilies/12.gif "ммм..."){kind=small}
приезжайте в гости! ![:]52](./images/smilies/52.gif "вздрогнем!"){kind=small}
у меня, наверное уже возрастное, сразу история из жизни.Пенка писал(а):понимаешь ты меня.. спасибо!
Опять же у каждого свое. Необходимо детальное обследование перед принятием решения.Арин писал(а):Меня б коснулось -я б крепко подумала.
И подольше от переходного возраста потянула.
Все тки организм перестраивается- не шутки шути.
|
|
![:]70](./images/smilies/70.gif "???"){kind=small}
